Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply
- PMID: 32786201
- DOI: 10.1056/NEJMc2021840
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply
Comment on
-
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.N Engl J Med. 2020 Aug 13;383(7):693-694. doi: 10.1056/NEJMc2021840. N Engl J Med. 2020. PMID: 32786198 No abstract available.
-
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.N Engl J Med. 2020 Aug 13;383(7):694. doi: 10.1056/NEJMc2021840. N Engl J Med. 2020. PMID: 32786199 No abstract available.
-
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.N Engl J Med. 2020 Aug 13;383(7):694-695. doi: 10.1056/NEJMc2021840. N Engl J Med. 2020. PMID: 32786200 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical